<p>股票 | 评级 | 目标价格 (港元)</p>
<p>KEYMED BIO-B(02162.HK) +4.400 (+7.593%)  空头头寸 1433 万美元; 比率 17.162%  | 超配 | 93.5 -&gt; 97</p>
<p>INNOVENT BIO(01801.HK) +8.650 (+11.556%)  空头头寸 2.7641 亿美元; 比率 19.410%  | 超配 | 130 -&gt; 135</p>
<p>LEADS BIOLABS-B(09887.HK) +0.900 (+1.479%)  空头头寸 54.967 万美元; 比率 5.201%  | 等权重 | 59 -&gt; 62</p>
<p>HUTCHMED(00013.HK) +0.490 (+2.754%)  空头头寸 561 万美元; 比率 11.319%  | 低配 -&gt; 等权重 | 21.4 -&gt; 21.3</p>
<p>REMEGEN(09995.HK) +4.150 (+5.256%)  空头头寸 1650 万美元; 比率 8.949%  | 等权重 | 89 -&gt; 98</p>
<p>INNOCARE(09969.HK) +0.460 (+4.100%)  空头头寸 823 万美元; 比率 16.150%  | 等权重 -&gt; 超配 | 19.6 -&gt; 17</p>
<p>DUALITYBIO-B(09606.HK) +17.200 (+8.222%)  空头头寸 842 万美元; 比率 6.536%  | 超配 | 493</p>
<p>ABBISKO-B(02256.HK) +0.160 (+1.670%)  空头头寸 147 万美元; 比率 21.819%  | 超配 | 22</p>
<p>ZAI LAB(09688.HK) +0.390 (+2.863%)  空头头寸 4975 万美元; 比率 39.140%  | 超配 | 19</p>
<p>VISEN PHARMA-B(02561.HK) -0.180 (-0.803%)  空头头寸 8.80 千美元; 比率 1.964%  | 超配 | 50</p>
<p>EVEREST MED(01952.HK) +1.400 (+4.871%)  空头头寸 529 万美元; 比率 9.764%  | 等权重 | 40</p>
<p>(香港股票报价延迟至少 15 分钟。空头数据截至 2026-05-29 12:25。)</p>

诺诚健华

信达生物

<p>摩根士丹利对几只中国生物科技股票提供了评级和目标价格。Keymed Bio-B（增持，目标价：97）、Innovent Bio（增持，目标价：135）和 DualityBio-B（增持，目标价：493）均出现了显著的价格上涨。Hutchmed 的评级从减持调整为持平（目标价：21.3）。其他股票如 Remegen 和 InnoCare 也获得了持平评级，目标价格分别调整为 98 和 17</p>

<p>Shares | Ratings | Target prices (HK$)</p>
<div class="lb-trans"><p>股票 | 评级 | 目标价格 (港元)</p>
</div><p>KEYMED BIO-B(02162.HK) +4.400 (+7.593%)  Short selling $14.33M; Ratio 17.162%  | Overweight | 93.5 -&gt; 97</p>
<div class="lb-trans"><p>KEYMED BIO-B(02162.HK) +4.400 (+7.593%)  空头头寸 1433 万美元; 比率 17.162%  | 超配 | 93.5 -&gt; 97</p>
</div><p>INNOVENT BIO(01801.HK) +8.650 (+11.556%)  Short selling $276.41M; Ratio 19.410%  | Overweight | 130 -&gt; 135</p>
<div class="lb-trans"><p>INNOVENT BIO(01801.HK) +8.650 (+11.556%)  空头头寸 2.7641 亿美元; 比率 19.410%  | 超配 | 130 -&gt; 135</p>
</div><p>LEADS BIOLABS-B(09887.HK) +0.900 (+1.479%)  Short selling $549.67K; Ratio 5.201%  | Equalweight | 59 -&gt; 62</p>
<div class="lb-trans"><p>LEADS BIOLABS-B(09887.HK) +0.900 (+1.479%)  空头头寸 54.967 万美元; 比率 5.201%  | 等权重 | 59 -&gt; 62</p>
</div><p>HUTCHMED(00013.HK) +0.490 (+2.754%)  Short selling $5.61M; Ratio 11.319%  | Underweight -&gt; Equalweight | 21.4 -&gt; 21.3</p>
<div class="lb-trans"><p>HUTCHMED(00013.HK) +0.490 (+2.754%)  空头头寸 561 万美元; 比率 11.319%  | 低配 -&gt; 等权重 | 21.4 -&gt; 21.3</p>
</div><p>REMEGEN(09995.HK) +4.150 (+5.256%)  Short selling $16.50M; Ratio 8.949%  | Equalweight | 89 -&gt; 98</p>
<div class="lb-trans"><p>REMEGEN(09995.HK) +4.150 (+5.256%)  空头头寸 1650 万美元; 比率 8.949%  | 等权重 | 89 -&gt; 98</p>
</div><p>INNOCARE(09969.HK) +0.460 (+4.100%)  Short selling $8.23M; Ratio 16.150%  | Equalweight -&gt; Overweight | 19.6 -&gt; 17</p>
<div class="lb-trans"><p>INNOCARE(09969.HK) +0.460 (+4.100%)  空头头寸 823 万美元; 比率 16.150%  | 等权重 -&gt; 超配 | 19.6 -&gt; 17</p>
</div><p>DUALITYBIO-B(09606.HK) +17.200 (+8.222%)  Short selling $8.42M; Ratio 6.536%  | Overweight | 493</p>
<div class="lb-trans"><p>DUALITYBIO-B(09606.HK) +17.200 (+8.222%)  空头头寸 842 万美元; 比率 6.536%  | 超配 | 493</p>
</div><p>ABBISKO-B(02256.HK) +0.160 (+1.670%)  Short selling $1.47M; Ratio 21.819%  | Overweight | 22</p>
<div class="lb-trans"><p>ABBISKO-B(02256.HK) +0.160 (+1.670%)  空头头寸 147 万美元; 比率 21.819%  | 超配 | 22</p>
</div><p>ZAI LAB(09688.HK) +0.390 (+2.863%)  Short selling $49.75M; Ratio 39.140%  | Overweight | 19</p>
<div class="lb-trans"><p>ZAI LAB(09688.HK) +0.390 (+2.863%)  空头头寸 4975 万美元; 比率 39.140%  | 超配 | 19</p>
</div><p>VISEN PHARMA-B(02561.HK) -0.180 (-0.803%)  Short selling $8.80K; Ratio 1.964%  | Overweight | 50</p>
<div class="lb-trans"><p>VISEN PHARMA-B(02561.HK) -0.180 (-0.803%)  空头头寸 8.80 千美元; 比率 1.964%  | 超配 | 50</p>
</div><p>EVEREST MED(01952.HK) +1.400 (+4.871%)  Short selling $5.29M; Ratio 9.764%  | Equalweight | 40</p>
<div class="lb-trans"><p>EVEREST MED(01952.HK) +1.400 (+4.871%)  空头头寸 529 万美元; 比率 9.764%  | 等权重 | 40</p>
</div><p>(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 12:25.)</p>
<div class="lb-trans"><p>(香港股票报价延迟至少 15 分钟。空头数据截至 2026-05-29 12:25。)</p>
</div>

M Stanley Ratings and TPs on China Biotech Stocks

AASTOCKS News

荣昌生物

和黄医药

博时恒生医疗保健(QDII-ETF)

华宝恒生港股通创新药精选ETF

创新药

国泰中证生物医药ETF

易方达中证生物科技主题ETF

国泰中证沪港深创新药产业ETF

天弘国证生物医药ETF

易方达沪深300医药ETF

香港医药

华夏恒生生物科技ETF(QDII)

富国恒生港股通创新药及医疗保健ETF

招商中证生物科技主题ETF

博时恒生港股通创新药精选ETF

南方恒生生物科技ETF(QDII)

生物科技ETF基金

华夏中证生物科技主题ETF

华夏医药ETF

汇添富国证港股通创新药ETF

摩根士丹利

康诺亚-B

维立志博-B

映恩生物-B

和誉-B

再鼎医药

维昇药业-B

云顶新耀

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

摩根士丹利对中国生物科技股票的评级和目标价格